

9. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395(10223): 507–513. Dostupné z DOI: <[https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)>.
10. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infect Control Hosp Epidemiol* 2021; 42(1): 84–88. Dostupné z DOI: <<https://doi.org/10.1017/ice.2020.368>>.
11. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. *J Infect* 2020; 81(2): 266–275. Dostupné z DOI: <<https://doi.org/10.1016/j.jinf.2020.05.046>>.
12. Vaughn VM, Gandhi T, Petty LA et al. Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study. *Clin Infect Dis* 2021; 72(10): e533–e541. Dostupné z DOI: <<https://doi.org/10.1093/cid/ciaa1239>>.
13. Buetti N, Mazzuchelli T, Lo Priore E et al. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. *J Infect* 2020; 81(2): e148–e149. Dostupné z DOI: <<https://doi.org/10.1016/j.jinf.2020.06.004>>.
14. Garcia-Vidal C, Sanjuan G, Moreno-García E et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect* 2021; 27(1): 83–88. Dostupné z DOI: <<https://doi.org/10.1016/j.cmi.2020.07.041>>.
15. Chedid M, Waked R, Haddad E et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. *J Infect Public Health* 2021; 14(5): 570–576. Dostupné z DOI: <<https://doi.org/10.1016/j.jiph.2021.02.001>>.
16. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; 323(11): 1061–1069. Dostupné z DOI: <<https://doi.org/10.1001/jama.2020.1585>>.
17. Wang D, Yin Y, Hu C et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. *Crit Care* 2020; 24(1): 188. Dostupné z DOI: <<https://doi.org/10.1186/s13054-020-02895-6>>.
18. Wang Z, Yang B, Li Q et al. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis* 2020; 71(15): 769–777. Dostupné z DOI: <<https://doi.org/10.1093/cid/ciaa272>>.
19. He Y, Li W, Wang Z, et al. Nosocomial infection among patients with COVID-19: a retrospective data analysis of 918 cases from a single center in Wuhan, China. *Infect Control Hosp Epidemiol* 2020; 41(8): 982–983. Dostupné z DOI: <<https://doi.org/10.1017/ice.2020.126>>.
20. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395(10223): 497–506. Dostupné z DOI: <[https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)>.
21. Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; 130(5): 2620–2629. Dostupné z DOI: <<https://doi.org/10.1172/JCI137244>>.
22. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020; 368: m1295. Dostupné z DOI: <<https://doi.org/10.1136/bmj.m1295>>.
23. Chen H, Guo J, Wang C et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 2020; 395(10226): 809–815. Dostupné z DOI: <[https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3)>.
24. Xu XW, Wu XX, Jiang XG et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020; 368: m606. Dostupné z DOI: <<https://doi.org/10.1136/bmj.m606>>.
25. Cao B, Wang Y, Wen D et al. A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med* 2020; 382(19): 1787–1799. Dostupné z DOI: <<https://doi.org/10.1056/NEJMoa2001282>>.
26. Zhao XY, Xu XX, Yin HS et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. *BMC Infect Dis* 2020; 20(1): 311. Dostupné z DOI: <<https://doi.org/10.1186/s12879-020-05010-w>>.
27. Borba MGS, Val FFA, Sampaio VS et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. *JAMA Netw Open* 2020; 3(4): e208857. Dostupné z DOI: <<https://doi.org/10.1001/jamanetworkopen.2020.8857>>.
28. Pedersen HP, Hildebrandt T, Poulsen A, et al. Initial experiences from patients with COVID-19 on ventilatory support in Denmark. *Dan Med J* 2020; 67(5): A04200232. PMID: 32351196.
29. Aggarwal S, Garcia-Telles N, Aggarwal G et al. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. *Diagnosis* 2020; 7(2): 91–96. Dostupné z DOI: <<https://doi.org/10.1515/dx-2020-0046>>.
30. Guan W, Ni Z, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; 382(18): 1708–1720. Dostupné z DOI: <<https://doi.org/10.1056/NEJMoa2002032>>.
31. Htoutou Sedláková M, Vojtová V, Hanulík V, et al. Rezistence enterobakterií k vybraným antibiotikům v souvislosti s jejich spotřebou. *Klin Farmakol Farm* 2012; 26(2): 61–66.
32. Urbánek K, Kolar M, Loveckova Y et al. Influence of 3rd generation cephalosporin utilization on the occurrence of ESBL-positive *Klebsiella pneumoniae* strains. *J Clin Pharm Ther* 2007; 32(4): 403–408. Dostupné z DOI: <<https://doi.org/10.1111/j.1365-2710.2007.00836.x>>.
33. Kolar M, Urbánek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. *Int J Antimicrob Agents* 2001; 17(5): 357–363. Dostupné z DOI: <[https://doi.org/10.1016/S0924-8579\(01\)00317-X](https://doi.org/10.1016/S0924-8579(01)00317-X)>.
34. Kim HS. Do an altered gut microbiota and an associated leaky gut affect COVID-19 severity? *mBio* 2021; 12(1): e03022-20. Dostupné z DOI: <<https://doi.org/10.1128/mBio.03022-20>>.
35. Martin E, Philbin M, Hughes G et al. Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic. *J Antimicrob Chemother* 2021; 76(1): 272–275. Dostupné z DOI: <<https://doi.org/10.1093/jac/dkaa400>>.
36. Sieswerda E, De Boer MGJ, Bonten MM et al. Recommendations for antibacterial therapy in adults with COVID-19 – An evidence based guideline. *Clin Microbiol Infect* 2021; 27(1): 61–66. Dostupné z DOI: <<https://doi.org/10.1016/j.cmi.2020.09.041>>.
37. World Health Organization. COVID-19 Clinical management: living guidance. WHO. [cit. 2021-09-01]. Dostupné z WWW: <<https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>>.
38. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. NICE. [cit. 2021-09-01]. Dostupné z WWW: <<https://www.nice.org.uk/guidance/ng191>>.
39. Cong W, Poudel AN, Alhusein N et al. Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic: A Scoping Review. *Antibiotics* 2021; 10(6): 745. Dostupné z DOI: <<https://doi.org/10.3390/antibiotics10060745>>.
40. Liu C, Wen Y, Wan W et al. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. *Int Immunopharmacol* 2021; 90: 107157. Dostupné z DOI: <<https://doi.org/10.1016/j.intimp.2020.107157>>.
41. Kolář M. Respirační infekce a jejich léčba. Maxdorf: Praha 2016. ISBN 978-80-7345-481-4.
42. Kolář M, Barďoň J, Rejman D. Zásady antibiotické léčby. VUP: Olomouc 2020. ISBN 978-80-244-5740-6.
43. Kolář M, Beneš J, Kolek V, et al. Klinický doporučený postup Nozokomiální pneumonie – antibiotická léčba. Národní portál klinických doporučených postupů [cit. 2021-09-01]. Dostupné z WWW: <<https://kdp.uzis.cz>>.
44. Torres A, Niederman M, Chastre J et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. *Eur Respir J* 2017; 50(3): 1700582. Dostupné z DOI: <<https://doi.org/10.1183/13993003.00582-2017>>.